|Trastuzumab is a humanized IgG1κ monoclonal antibody targeting HER2.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Biosimilar drugs: Mylan laboratories Inc. and Biocon Limited are partnering the marketing of MYL-1401O (Hertraz®, Canmab®) a biosimilar already approved in India. A Biologics License Application (BLA) for MYL-1401O has been accepted by the FDA, and it is also under review by the EMA. Herzum® (CT-P6; Celltrion Inc.) is approved in Korea. These biosimilars are all approved for the same clinical indications as the reference drug. CT-P6 as Credima® is pre-registered with the EMA and SB3 is in Samsung Bioepis' development pipeline.